Results: 1-10 |
Results: 10

Authors: Salgado, R Vermeulen, PB Van Marck, E Benoy, I Dirix, L
Citation: R. Salgado et al., Correspondence re: M.L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6 : 3147-3152, 2000., CLIN CANC R, 7(5), 2001, pp. 1481-1482

Authors: Schellens, JHM Dombernowsky, P Cassidy, J Epelbaum, R Dirix, L Cox, EH Wanders, J Calabresi, F Paridaens, R Monfardini, S Wolff, J Loos, WJ Verweij, J Pavlidis, N Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590

Authors: Colpaert, C Vermeulen, P van Beest, P Goovaerts, G Weyler, J Van Dam, P Dirix, L Van Marck, E
Citation: C. Colpaert et al., Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breastcancer patients, HISTOPATHOL, 39(4), 2001, pp. 416-425

Authors: Colpaert, C Vermeulen, P Van Marck, E Dirix, L
Citation: C. Colpaert et al., The presence of a fibrotic focus is an independent predictor of early metastasis in lymph node-negative breast cancer patients, AM J SURG P, 25(12), 2001, pp. 1557-1558

Authors: Colpaert, C Vermeulen, P Jeuris, W van Beest, P Goovaerts, G Weyler, J Van Dam, P Dirix, L Van Marck, E
Citation: C. Colpaert et al., Early distant relapse in 'node-negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of theprimary tumour, J PATHOLOGY, 193(4), 2001, pp. 442-449

Authors: Van Cutsem, E Findlay, M Osterwalder, B Kocha, W Dalley, D Pazdur, R Cassidy, J Dirix, L Twelves, C Allman, D Seitz, JF Scholmerich, J Burger, HU Verweij, J
Citation: E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activityin advanced colorectal cancer: Results of a randomized phase II study, J CL ONCOL, 18(6), 2000, pp. 1337-1345

Authors: Van Cutsem, E Cunningham, D Huinink, WWT Punt, CJA Alexopoulos, CG Dirix, L Symann, M Blijham, GH Cholet, P Fillet, G Van Groeningen, C Vannetzel, JM Levi, F Panagos, G Unger, C Wils, J Cote, C Blanc, C Herait, P Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59

Authors: Schrijvers, D Catimel, G Highley, M Hoppener, FJP Dirix, L De Bruijn, E Droz, JP Van Oosterom, AT
Citation: D. Schrijvers et al., KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study, ANTI-CANC D, 10(7), 1999, pp. 633-639

Authors: Lauwers, P Hubens, G Hendriks, J Vermeulen, P Schuerwegh, A Stevens, WJ De Clerck, LS Dirix, L Van Marck, E Hubens, A Eyskens, E
Citation: P. Lauwers et al., Effects of suramin on anastomotic colon tumors in a rat model, EUR SURG RE, 31(4), 1999, pp. 347-356

Authors: Van Cutsem, E Pozzo, C Starkhammar, H Dirix, L Terzoli, E Cognetti, E Humblet, Y Garufi, C Filez, L Gruia, G Cote, C Barone, C
Citation: E. Van Cutsem et al., A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer, ANN ONCOL, 9(11), 1998, pp. 1199-1204
Risultati: 1-10 |